Expansion in Healthcare Division in Global market

Export Order Hard CurrencyBusiness Updates View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹3287.15

prior close

₹3122.80

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-4.5% vs market

Edible Oil peers, median of 23sector-1.9%-3.1% vs sector

On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 3.1 pts less than its Edible Oil peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0-0.5-4.5-1.9-3.1

Next day

-9.7+0.5-10.3-1.7-8.0

-14.3+1.5-15.8-0.3-13.9

-18.5+1.1-19.6-0.6-17.9

-22.6+0.7-23.3-0.6-22.0

-26.5+1.1-27.6-0.7-25.8

-33.7+1.8-35.5-0.7-32.9

15d

-51.3-0.4-51.0-2.3-49.0

-60.4+1.0-61.3-3.4-56.9

-49.7-5.8-43.9-8.1-41.6

-58.6-8.9-49.6-14.6-43.9

UpDownMarket · Nifty Microcap 250Sector · Edible Oil peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CIAN Agro Industries has secured and executed its first export order for Ethiopia under the UAE Aid Program, marking entry into the global pharmaceutical market through its Healthcare Division. The order was facilitated by partner Inthera Pharmamed Biotech Pvt. Ltd., with products manufactured by Bharat Serums and Vaccines Limited, a well-known Indian pharma company. This shipment is the launch of a broader humanitarian healthcare initiative aimed at improving medical access in Ethiopia. No financial value or order size was disclosed in the filing.

Likely market impact

Positive for the stock as it signals the company's diversification into pharma exports and global markets, but the lack of disclosed order value limits the ability to gauge actual revenue impact on shareholders.